Progression-directed ablative radiotherapy improves event-free survival in oligoprogressive NSCLC - Top-Institutions - MDSpire

Progression-directed ablative radiotherapy improves event-free survival in oligoprogressive NSCLC

  • By

  • Lorenzo De Sanctis

  • Riccardo Ray Colciago

  • Giulia Rossano

  • Matteo Ferrari

  • Matteo Mombelli

  • Ilenia Manno

  • Federica Ferrario

  • Sara Saufi

  • Valeria Faccenda

  • Denis Panizza

  • Gaia Passarella

  • Stefania Canova

  • Diego Luigi Cortinovis

  • Stefano Arcangeli

  • May 25, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology

  • #2

    University of California, Los Angeles
    University of California, Los Angeles

    Los Angeles, California

    Key Differentiators

    • Oncology

  • #3

    Radiation Therapy Oncology Group
    Radiation Therapy Oncology Group

    Philadelphia, Pennsylvania

    Key Differentiators

    • Oncology

  • #4

    Levine Cancer Institute
    Levine Cancer Institute

    Charlotte, North Carolina

    Key Differentiators

    • Oncology

  • #5

    Faculdade de Medicina do ABC
    Faculdade de Medicina do ABC

    Santo André, São Paulo

    Key Differentiators

    • Oncology

Original Source(s)

Progression-directed ablative radiotherapy improves event-free survival in oligoprogressive NSCLC

  • by Lorenzo De Sanctis, Riccardo Ray Colciago, Giulia Rossano, Matteo Ferrari, Matteo Mombelli, Ilenia Manno, Federica Ferrario, Sara Saufi, Valeria Faccenda, Denis Panizza, Gaia Passarella, Stefania Canova, Diego Luigi Cortinovis, Stefano Arcangeli

  • May 25, 2026

Related Content

FEBAIR microsurgical principles in meningiomas and recurrence: a long-term follow-up series

Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy

Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases